Nafazatrom as a lipoxygenase inhibitor
US4657924A · kind A · utility
0Cited by
2References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 25, 1985 |
| Grant date | Apr 14, 1987 |
| Priority date | — |
| Expiry date | Mar 25, 2005 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/415
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of inhibiting lipoxygenase in a patient, for the prophylaxis and/or treatment of ischaemias and disorders in cardiac rhythm and of rheumatic, allergic and asthmatic diseases, oedemas, pulmonary embolisms, pulmonary hypertension, oxygen intoxications and ulcerations which comprises administering to such patient an effective amount of nafazatrom.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.